Trial halted early: testing new combo for tough lung cancers
NCT ID NCT05141357
Summary
This study tested whether adding a new oral drug, HBI-8000, to an existing immunotherapy (pembrolizumab) could help control advanced non-small cell lung cancer. It was for adults with a specific biomarker whose cancer had progressed. The main goals were to see if the combination was safe and if it could stop the cancer from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CBCC Global Research, Inc at Comprehensive Blood and Cancer Center
Bakersfield, California, 93309, United States
-
Cotton O'Neil Clinical Research Center
Topeka, Kansas, 66606, United States
-
Frederick Health-JMSCI
Frederick, Maryland, 21702, United States
-
Hematology Oncology Associates Of The Treasure Coast
Port Saint Lucie, Florida, 34952, United States
-
Midewestern Regional Medical Center, LLC
Zion, Illinois, 60099, United States
-
Southeastern Regional Medical Center
Newnan, Georgia, 30265, United States
-
Western Regional Medical Center
Goodyear, Arizona, 85338, United States
Conditions
Explore the condition pages connected to this study.